{
    "id": 10006,
    "fullName": "BCL2A1 dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "BCL2A1 dec exp indicates decreased expression of the Bcl2a1 protein and/or mRNA. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 597,
        "geneSymbol": "BCL2A1",
        "terms": [
            "BCL2A1",
            "ACC-1",
            "ACC-2",
            "ACC1",
            "ACC2",
            "BCL2L5",
            "BFL1",
            "GRS",
            "HBPA1"
        ]
    },
    "variant": "dec exp",
    "createDate": "08/04/2015",
    "updateDate": "08/17/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2684,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, knockdown of Bcl2a1 in renal cell carcinoma cells increased sensitivity to ABT-737 in culture (PMID: 20576107).",
            "molecularProfile": {
                "id": 10009,
                "profileName": "BCL2A1 dec exp"
            },
            "therapy": {
                "id": 1772,
                "therapyName": "ABT-737",
                "synonyms": null
            },
            "indication": {
                "id": 4450,
                "name": "renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3385,
                    "pubMedId": 20576107,
                    "title": "Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20576107"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 10009,
            "profileName": "BCL2A1 dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}